Skip to main content

Table 2 Outcomes of the sensitivity analysis and test of publication bias

From: An efficacy and safety evaluation of montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: a meta-analysis

Outcomes

No. of studies

Sensitivity analysis

Egger’ s test

HR/ORs (95% CI)

Robust

P value

Total effective rate

5

1.30 (1.18, 1.43) to 1.34 (1.20, 1.50)

Yes

0.087

Relapse rate

6

0.42 (0.22, 0.79) to 0.60 (0.34, 1.05)

No

0.933

The score of cough

6

-0.88 (-1.02, -0.74) to 0.00 (-0.28, 0.28)

No

0.055

Cough remission time

3

-3.19 (-3.87, -2.52) to -2.26 (-2.80, -1.72)

Yes

0.732

FEV1%

4

1.29 (-0.97, 3.54) to 3.30 (1.09, 5.50)

No

0.668

PEF%

4

1.73 (-0.73, 4.18) to 4.84 (0.13, 9.55)

No

0.242

Headache

5

1.00 (0.20, 4.90) to 1.73 (0.35, 8.46)

Yes

0.060

Dizzy

4

0.69 (0.11, 4.33) to 1.77 (0.29, 10.77)

Yes

0.346

Hoarseness

6

0.70 (0.21, 2.37) to 1.00 (0.27, 3.63)

Yes

0.474

Abdominal pain

6

0.96 (0.35, 2.67) to 1.58 (0.48, 5.19)

Yes

0.080

Total complication

9

0.98 (0.57, 1.71) to 1.15 (0.63, 2.09)

Yes

0.148

  1. HR Hazard ratio, OR Odds ratio, CI Confidence interval, FEV1% Percentage of forced expiratory volume in 1 second, PEF% Percentage of predicted peak expiratory flow